The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation

BJU International

Volumn 97, Issue 6, 2006, Pages 1242-1246

  Nickel, J Curtis ^a   Elhilali, Mostafa ^b   Emberton, Mark ^c   Vallancien, Guy ^d,e  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e NONE

Author keywords

blockers; Alfuzosin; BPH; LUTS; Painful ejaculation; Prostatitis; Sexual dysfunction

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; CHRONIC PROSTATITIS; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL PRACTICE; ORTHOSTATIC HYPOTENSION; PAINFUL EJACULATION; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; URETHRA DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; EJACULATION; HUMANS; MALE; MIDDLE AGED; PAIN; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 33745200971     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06171.x     Document Type: Article

References (20)

1. Litwin MS, McNaughton-Collins M, Fowler FJ et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999 162: 369 75
2. Shoskes DA, Landis JR, Wang Y et al. Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004 172: 542 7
3. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003 44: 637 49
4. Vallancien G, Emberton M, Harving N, van Moorselaar RJ for the Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003 169: 2257 61
5. Frankel SJ, Donovan JL, Peters TJ et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998 51: 677 85
6. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. BMJ 2002 324: 1059 61
7. Nickel JC, Elhilali M, Vallancien G for the ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int 2005 95: 571 4
8. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000 37: 306 13
9. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001 58: 953 9
10. Roehrborn CG, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003 92: 257 61
11. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005 95: 1006 12
12. van Moorselaar RJ, Hartung R, Emberton M et al.; ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005 95: 603 8
13. Barry MJ, Fowler FJ O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992 148: 1549 57
14. Roehrborn CG, Kaplan SA, Noble WD et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. results from the MTOPS study. J Urol 2005 173 ( Suppl. 346, A1277
15. Cheah PY, Liong ML, Yuen KH et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003 169: 592 6
16. Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized double-blind placebo controlled pilot study. Urology 2003 62: 425 9
17. Nickel JC, Narayan P, MacKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004 171: 1594 7
18. Alexander RB, Propert KJ, Schaeffer AJ et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomzed, double-blind trial. Ann Int Med 2004 141: 581 9
19. Nickel JC. The three As of chronic prostatitis therapy: antibiotics, α-blockers and anti-inflammatories. What is the evidence? BJU Int 2004 94: 1230 3
20. Trevisani M, Campi B, Nicoletti. P, Harrison S, Geppetti P. Alpha1-adrenoreceptors are expressed by and stimulate nociceptive and pro-inflammatory sensory neurons in the rat urinary tract. Eur Urol 2005 47 ( Suppl. A140